Abstract
The current situation in the treatment of metastatic breast cancer is reviewed. Overall the concurrent use of endocrine treatment and chemotherapy does not improve the therapeutic results as compared to a treatment encompassing only one modality. However, results diverge widely in different subgroups. Data emerging from various randomized trials are beginning to define subgroups of patients, who should be treated differently. Such data are discussed and their importance for future trials in the field of advanced breast cancer reviewed.
| Original language | English |
|---|---|
| Pages (from-to) | 1129-1134 |
| Number of pages | 6 |
| Journal | Journal of Steroid Biochemistry |
| Volume | 23 |
| Issue number | 6 PART 2 |
| DOIs | |
| Publication status | Published - 1985 |
ASJC Scopus subject areas
- Biochemistry
- Endocrinology